Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia

Masayuki Ide1, Tetsuo Ohnishi, Miyuki Murayama

  • 1Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan.

Journal of Neurochemistry
|September 22, 2006
PubMed

Insights

This study investigated the AKT1-GSK3beta signaling pathway in schizophrenia. Findings did not support a theory of attenuated signaling in schizophrenia, highlighting potential confounds in postmortem brain studies.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • The AKT1-GSK3beta signaling pathway is implicated in schizophrenia pathogenesis.
  • Previous studies suggested attenuated AKT1 signaling and reduced GSK3beta phosphorylation in schizophrenia.

Purpose of the Study:

  • To evaluate the theory of attenuated AKT1-GSK3beta signaling in schizophrenia.
  • To conduct genetic and protein expression analyses in Japanese subjects.

Main Methods:

  • Family-based association test of the AKT1 gene.
  • Western blot analysis of AKT and phosphorylated GSK3beta in postmortem brain samples.
  • Analysis of AKT-GSK3beta signaling in lymphocytes.

Main Results:

  • No significant association between AKT1 and schizophrenia in Japanese subjects.
  • Expression levels of AKT and phosphorylated GSK3beta did not support the attenuated signaling theory.
  • No attenuated AKT-GSK3beta signaling observed in schizophrenic lymphocytes.
  • Phosphorylated GSK3beta and AKT levels correlated with postmortem interval and brain pH, respectively.

Conclusions:

  • The study failed to support reduced AKT-GSK3beta signaling in schizophrenia.
  • Postmortem factors like interval and pH can influence phosphorylation levels, necessitating caution in interpretation.

Related Concept Videos

Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...